Apolizumab
Alternative Names: Hu1D10; Monoclonal antibody SMART 1D10; Remitogen; SMART 1D10 antibodyLatest Information Update: 25 Sep 2021
At a glance
- Originator PDL BioPharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 11 Sep 2003 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
- 26 Jun 2002 Discontinued - Phase-II for Non-Hodgkin's lymphoma in USA (Infusion)
- 21 May 2002 Phase-I clinical trials in Solid tumours in USA (unspecified route)